850 related articles for article (PubMed ID: 15731170)
1. Epigenetic mechanisms in the dopamine D2 receptor-dependent inhibition of the prolactin gene.
Liu JC; Baker RE; Chow W; Sun CK; Elsholtz HP
Mol Endocrinol; 2005 Jul; 19(7):1904-17. PubMed ID: 15731170
[TBL] [Abstract][Full Text] [Related]
2. Association of the mSin3A-histone deacetylase 1/2 corepressor complex with the mouse steroidogenic acute regulatory protein gene.
Clem BF; Clark BJ
Mol Endocrinol; 2006 Jan; 20(1):100-13. PubMed ID: 16109738
[TBL] [Abstract][Full Text] [Related]
3. The zinc finger Ikaros transcription factor regulates pituitary growth hormone and prolactin gene expression through distinct effects on chromatin accessibility.
Ezzat S; Yu S; Asa SL
Mol Endocrinol; 2005 Apr; 19(4):1004-11. PubMed ID: 15618287
[TBL] [Abstract][Full Text] [Related]
4. Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex.
Zhang Y; Dufau ML
J Biol Chem; 2002 Sep; 277(36):33431-8. PubMed ID: 12091390
[TBL] [Abstract][Full Text] [Related]
5. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription.
Zhang Y; Fatima N; Dufau ML
Mol Cell Biol; 2005 Sep; 25(18):7929-39. PubMed ID: 16135786
[TBL] [Abstract][Full Text] [Related]
6. Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene.
Liu JC; Baker RE; Sun C; Sundmark VC; Elsholtz HP
J Biol Chem; 2002 Sep; 277(39):35819-25. PubMed ID: 12121979
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation.
Zika E; Greer SF; Zhu XS; Ting JP
Mol Cell Biol; 2003 May; 23(9):3091-102. PubMed ID: 12697811
[TBL] [Abstract][Full Text] [Related]
8. Dynamic histone acetylation/deacetylation with progesterone receptor-mediated transcription.
Aoyagi S; Archer TK
Mol Endocrinol; 2007 Apr; 21(4):843-56. PubMed ID: 17227884
[TBL] [Abstract][Full Text] [Related]
9. Aberrant dynamics of histone deacetylation at the thyrotropin-releasing hormone gene in resistance to thyroid hormone.
Ishii S; Yamada M; Satoh T; Monden T; Hashimoto K; Shibusawa N; Onigata K; Morikawa A; Mori M
Mol Endocrinol; 2004 Jul; 18(7):1708-20. PubMed ID: 15131262
[TBL] [Abstract][Full Text] [Related]
10. The zinc finger repressor, ZBP-89, recruits histone deacetylase 1 to repress vimentin gene expression.
Wu Y; Zhang X; Salmon M; Zehner ZE
Genes Cells; 2007 Aug; 12(8):905-18. PubMed ID: 17663720
[TBL] [Abstract][Full Text] [Related]
11. The Pit-1beta domain dictates active repression and alteration of histone acetylation of the proximal prolactin promoter.
Diamond SE; Gutierrez-Hartmann A
J Biol Chem; 2000 Oct; 275(40):30977-86. PubMed ID: 10921928
[TBL] [Abstract][Full Text] [Related]
12. G(i) alpha 2- and G(o) alpha-mediated signaling in the Pit-1-dependent inhibition of the prolactin gene promoter. Control of transcription by dopamine D2 receptors.
Lew AM; Yao H; Elsholtz HP
J Biol Chem; 1994 Apr; 269(16):12007-13. PubMed ID: 8163504
[TBL] [Abstract][Full Text] [Related]
13. HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells.
Kong X; Fang M; Li P; Fang F; Xu Y
J Mol Cell Cardiol; 2009 Mar; 46(3):292-9. PubMed ID: 19041327
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation.
Mulholland NM; Soeth E; Smith CL
Oncogene; 2003 Jul; 22(31):4807-18. PubMed ID: 12894222
[TBL] [Abstract][Full Text] [Related]
15. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
[TBL] [Abstract][Full Text] [Related]
16. Thanatos-associated protein 7 associates with template activating factor-Ibeta and inhibits histone acetylation to repress transcription.
Macfarlan T; Parker JB; Nagata K; Chakravarti D
Mol Endocrinol; 2006 Feb; 20(2):335-47. PubMed ID: 16195249
[TBL] [Abstract][Full Text] [Related]
17. Integration of prolactin and glucocorticoid signaling at the beta-casein promoter and enhancer by ordered recruitment of specific transcription factors and chromatin modifiers.
Kabotyanski EB; Huetter M; Xian W; Rijnkels M; Rosen JM
Mol Endocrinol; 2006 Oct; 20(10):2355-68. PubMed ID: 16772529
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase A-dependent recruitment of RNA polymerase II, C/EBP beta and NF-Y to the rat GTP cyclohydrolase I proximal promoter occurs without alterations in histone acetylation.
Kapatos G; Vunnava P; Wu Y
J Neurochem; 2007 May; 101(4):1119-33. PubMed ID: 17394555
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding.
Hu J; Colburn NH
Mol Cancer Res; 2005 Feb; 3(2):100-9. PubMed ID: 15755876
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Duan H; Heckman CA; Boxer LM
Mol Cell Biol; 2005 Mar; 25(5):1608-19. PubMed ID: 15713621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]